Fig. 5

Quantification of the fluorescence intensity of in vivo NIRF imaging using cetuximab-Cy7 probe in OC tumor models. The T/B ratios for (A) 1.1 µg cetuximab-Cy7, (B) 3.3 µg cetuximab-Cy7, (C) 10 µg cetuximab-Cy7 and (D) 30 µg cetuximab-Cy7 groups at all time points. Quantification of fluorescence intensity of (E) 30 µg mouse isotype IgG-Cy7 and (F) 30 µg cetuximab-Cy7 groups were shown for tumor and liver (n = 3). The mice were divided into 10 groups with 3 mice in each group, respectively intravenously injected with PBS, free Cy7, 1.1 µg, 3.3 µg, 10 µg, 30 µg dose of cetuximab-Cy7 or IgG-Cy7. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. The control groups including PBS, free Cy7 dye and mouse isotype IgG-Cy7 were also used in our previous work [22]. The corresponding images in the control groups in Fig. 5A -E were reprinted with permission from reference 22. NIRF: near-infrared fluorescence; Cetuximab-Cy7: cetuximab-cyanine7; OC: ovarian cancer; T/B: tumor-to-background; IgG-Cy7: immunoglobulin G-cyanine7; PBS: phosphate-buffered saline; hpi: time post injection